Additionally, a newly developed drug treatments, Finerenone, the non-steroidal mineralocorticoid receptor antagonist, has demonstrated significant promise in the treatment of DKD (Fujii and Shibata, 2023). The gene discussed is NR3C2; the disease is diabetic kidney disease.